Q-Line Biotech Ltd. (QLINE) — Tipsheet https://tipsheet.markets/company/qline/ Every Tipsheet Editorial note covering Q-Line Biotech Ltd. (QLINE), newest first. Grounded in BSE/NSE primary-source filings. en-in Mon, 06 Jul 2026 10:22:48 GMT Q-Line Biotech's reagent shift lifts gross margin 750 bps, targets 30-35% growth https://tipsheet.markets/qline-q-line-biotech-s-reagent-shift-lifts-gross-margin-750-bps-targets-30-35-growth-111558/ https://tipsheet.markets/qline-q-line-biotech-s-reagent-shift-lifts-gross-margin-750-bps-targets-30-35-growth-111558/ Tue, 23 Jun 2026 17:39:40 GMT FY26 gross margin hits 60.8% as manufactured reagents replace imports; FY27 guidance backed by 300-400 new analyzer installations and ₹10 cr CDMO target. FY26 gross margin hits 60.8% as manufactured reagents replace imports; FY27 guidance backed by 300-400 new analyzer installations and ₹10 cr CDMO target.

What’s new

  • FY26 revenue up 9% to ₹341.7 cr, gross margin up 750 bps to 60.8%.
  • FY27 revenue growth guided at 30-35%, with 300-400 new analyzer installations planned.
  • Lucknow Unit 4 operational; can support 3-4x current reagent business without new capex.

Why it matters

The 750 bps gross margin gain to 60.8% confirms the shift to manufactured reagents is working. FY27 guidance is ambitious but backed by specific drivers: recurring revenue from 1,550+ analyzers and a ₹10 cr CDMO target. The main risk remains geographic concentration with 77% of revenue from Uttar Pradesh.

What we’re watching

  • Progress on 300-400 new analyzer installations and reagent revenue per device.
  • International expansion in Middle East and Africa via Dubai manager and partnerships.
  • Whether CDMO and export targets materialize and reduce geographic concentration.

The full read

Q-Line's FY26 results show a clear shift: gross margin climbed 750 bps to 60.8%, the new Lucknow Unit 4 can support 3-4 times current reagent business without new capex, and the installed base of 1,550+ Selectra Pro M analyzers generates ₹25,000–30,000 per month per device in reagent revenue. FY27 guidance of 30–35% revenue growth is backed by specific drivers: 300-400 new analyzer installations, ₹6 cr in exports, and a ₹10 cr CDMO target. The company is reducing its reliance on Uttar Pradesh, which still accounts for 77% of revenue, aiming for a 50-50 B2G/trade mix by FY28. The next test: execution on international expansion and CDMO timelines.

Primary source: NSE

]]> Concalls Tipsheet Editorial